Last reviewed · How we verify
Satin
At a glance
| Generic name | Satin |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Proprioceptive Neuromuscular Training and Sensory Re-education in Patients With Diabetic Peripheral Neuropathy (NA)
- Effects of Motor and Sensory Exercises on Hand Functions (NA)
- The Effect of Smelling the Scent of Infants Hospitalized in the Neonatal Intensive Care Unit (NA)
- Impact Of Early Cognitive Rehabilitation On Functional Outcomes Following Moderate Traumatic Brain Injury (NA)
- Postprandial Monocyte Maturation and Vascular Dysfunction Following High-Fat Meals - Study 1 (NA)
- A Trial Comparing a Diet Including Products Aimed at Targeting Satiety (NA)
- A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins (PHASE2)
- SATIN: Satiety Innovation. Study 2- University of Aberdeen (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Satin CI brief — competitive landscape report
- Satin updates RSS · CI watch RSS
- Pfizer portfolio CI